An Overview of NanoCluster Powder Formulation Technology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

An Overview of NanoCluster Powder Formulation Technology
The authors describe a technique designed to yield low-density powders with a tailored particle-size distribution over a broad range of respiratory flow rates.


Pharmaceutical Technology
Volume 10, Issue 34, pp. 72-78

References

1. J.S. Patton and P.R. Byron, Nat. Rev. Drug Discov. 6 (1), 67–74 (2007).

2. G. Scheuch et al., Adv. Drug Deliv. Rev. 58, 996–1008 (2006).

3. N. Rasenack, H. Steckel, and B.W. Muller, J. Pharm. Sci. 92 (1), 35–44 (2003).

4. M.J. Telkoand and A.J. Hickey, Respir. Care 50, 1209–1227 (2005).

5. C.J. Musante et al., J. Pharm. Sci. 91 (7), 1580–1590 (2002).

6. M. Sakagami, Adv. Drug Deliv. Rev. 58, 1030–1060 (2006).

7. T.M. Crowder et al., Pharm. Res. 19 (3), 239–245 (2002).

8. J.C. Sung, B.L. Pulliam, and D.A. Edwards, Trends Biotechnol. 25 (12), 563–570 (2007).

9. Y.L. Wong et al., Proc. Natl. Acad. Sci. U.S.A. 104, 2591–2595 (2007).

10. J.C. Sung et al., Pharm. Res. 26 (8), 1847–1855 (2009).

11. R. Gupta et al., Aerosol Sci. Technol. 37 (8), 672–681 (2003).

12. X. Li et al., Int. J. Pharm. 303 (1–2), 113–124 (2005).

13. J.D. Rabinowitz, J. Pharmacol. Exp. Ther. 309 (5), 769–775 (2004).

14. R. Damani et al., 15th International Congress of the International Society for Aerosols in Medicine (Perth, Australia, 2005).

15. L. Kemp et al., J. Allergy Clin. Immunol. 123 (3), 729 (2009).

16. E. Derom and R.A. Pauwels, Clin. Pharmacokinet. 44 (8), 815–836 (2005).

17. L. Shi, C.J. Plumley, and C. Berkland, Langmuir 23 (22), 10897–10901 (2007).

18. N. El-Gendy et al., J. Pharm. Sci. 98 (8), 2731–2746 (2009).

19. C. Plumley et al., Int. J. Pharm. 369 (1–2), 136–143 (2009).

20. N. El-Gendy and C. Berkland, Pharm. Res. 26 (7), 1752–1763 (2009).

21. L.J. Peek, L. Roberts, and C. Berkland, Langmuir 24 (17), 9775–9783 (2008).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here